Opus Genetics (NASDAQ: IRD) adds change-in-control tax reimbursements
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Opus Genetics, Inc. entered into Change in Control Bonus Payment Agreements on April 1, 2026 with its Chief Executive Officer, Chief Financial Officer, Chief Operating Officer, and Chief Scientific and Development Officer. These agreements provide that the company will reimburse each executive for any excise taxes incurred under Section 4999 of the Internal Revenue Code in connection with a change in control of the company.
The agreements are based on a common form, which is filed as Exhibit 10.1 and incorporated by reference, giving investors access to the full contractual terms around potential change-in-control-related tax reimbursements for the senior leadership team.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 5.02, 9.01
2 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Agreement date: April 1, 2026
Executives covered: 4 executives
Tax code section: Section 4999
+1 more
4 metrics
Agreement date
April 1, 2026
Date Change in Control Bonus Payment Agreements were entered
Executives covered
4 executives
CEO, CFO, COO, Chief Scientific and Development Officer
Tax code section
Section 4999
Internal Revenue Code excise tax referenced in the agreements
Exhibit number
Exhibit 10.1
Form of Change in Control Bonus Agreement filed with the report
Key Terms
Change in Control Bonus Payment Agreement, excise taxes, Section 4999 of the Internal Revenue Code of 1986, as amended, emerging growth company
4 terms
Change in Control Bonus Payment Agreement financial
"entered into a Change in Control Bonus Payment Agreement with each of"
excise taxes financial
"the Company will reimburse the Executives for any excise taxes incurred"
Excise taxes are charges levied by governments on specific goods, activities, or services—commonly on items like fuel, tobacco, alcohol, or certain manufacturing activities—paid by producers or sellers and often built into the final price. For investors, they matter because higher or changing excise taxes can raise a company’s costs, reduce consumer demand, or alter profit margins in affected industries, much like a hidden toll that changes the economics of doing business.
Section 4999 of the Internal Revenue Code of 1986, as amended regulatory
"in connection with a change in control of the Company under Section 4999 of the Internal Revenue Code"
emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
FAQ
What did Opus Genetics (IRD) change regarding executive compensation?
Opus Genetics approved Change in Control Bonus Payment Agreements for its CEO, CFO, COO, and Chief Scientific and Development Officer. These agreements address how certain taxes tied to a future change in control of the company would be handled for these senior executives.
Which Opus Genetics (IRD) executives are covered by the new agreements?
The agreements cover Dr. George Magrath, Robert Gagnon, Joseph Schachle, and Dr. Ashwath Jayagopal. They serve as Chief Executive Officer, Chief Financial Officer, Chief Operating Officer, and Chief Scientific and Development Officer, aligning change-in-control tax treatment across the top leadership team.
How do the new Opus Genetics (IRD) agreements treat excise taxes?
The company agreed to reimburse the covered executives for any excise taxes owed under Section 4999 of the Internal Revenue Code. These taxes can arise from certain payments triggered by a change in control, and the agreements shift that specific tax cost from the executives to the company.
When did Opus Genetics (IRD) approve the change-in-control bonus agreements?
Opus Genetics entered into the Change in Control Bonus Payment Agreements on April 1, 2026. This date marks when the company formally committed to the excise tax reimbursement protections tied to potential future change-in-control events affecting its senior executives.
Where can investors find the full Opus Genetics (IRD) agreement terms?
The full terms are contained in the Form of Change in Control Bonus Agreement filed as Exhibit 10.1. That exhibit, incorporated by reference, provides detailed legal language on the executives’ rights and the company’s obligations if a change in control occurs.